Biology Reference
In-Depth Information
allowed us to re-evaluate the magnitude and functional nature of CD8
T cells
during the di¨erent stages of HIV-1 infection. Importantly, this evaluation has
allowed us to rethink therapeutic strategies and ®nd mechanisms for switching
on defective antigen-speci®c CD8
T cells and mobilize their anti-HIV CTL
activity during chronic disease.
REFERENCES
Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael
AJ, Davis MM. 1996. Phenotypic analysis of antigen-speci®c T lymphocytes. Science 274: 94±
96.
Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon
C, Spina CA, et al. 2000. HIV-speci®c CD8() T cells produce antiviral cytokines but are im-
paired in cytolytic function. J Exp Med 192: 63±75.
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J.
1997. Positive e¨ects of combined antiretroviral therapy on CD4
T cell homeostasis and func-
tion in advanced HIV disease. Science 277: 112±116.
Boniface JJ, Rabinowitz JD, Wul®ng C, Hampl J, Reich Z, Altman JD, Kantor RM, Beeson C,
McConnell HM, Davis MM. 1998. Initiation of signal transduction through the T cell receptor
requires the multivalent engagement of peptide/MHC ligands. Immunity 9: 459±466.
Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-speci®c CD8
cytotoxic
T-lymphocyte activity associated with control of viremia in primary human immunode®ciency
virus type 1 infection. J Virol 68: 6103±6110.
Borrow P, Lewicki H, Wei X, Horwitz MS, Pe¨er N, Meyers H, Nelson JA, Gairin JE, Hahn BH,
Oldstone MB, Shaw GM. 1997. Antiviral pressure exerted by HIV-1-speci®c cytotoxic T lym-
phocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
[see comments]. Nat Med 3: 205±211.
Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, Korber B, Wentworth P, Buch-
binder SP, Wolinsky S, Walker BD, Kalams SA. 1998. Lack of strong immune selection pres-
sure by the immunodominant, HLA- A*0201-restricted cytotoxic T lymphocyte response in
chronic human immunode®ciency virus-1 infection. J Clin Invest 101: 2559±2566.
Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ,
Rickinson AB. 1998. Direct visualization of antigen-speci®c CD8
T cells during the primary
immune response to Epstein-Barr virus in vivo. J Exp Med 187: 1395±1402.
Candore G, Romano GC, D'Anna C, Di Lorenzo G, Gervasi F, Lio D, Modica MA, Potestio M,
Caruso C. 1998. Biological basis of the HLA-B8,DR3-associated progression of acquired im-
mune de®ciency syndrome. Pathobiology 66: 33±37.
Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder
S, Hoots K, O'Brien SJ. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 dis-
advantage. Science 283: 1748±1752.
da Silva J, Hughes AL. 1998. Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host
strategy to constrain parasite adaptation: evidence from the nef gene of human immuno-
de®ciency virus 1 (HIV-1). Mol Biol Evol 15: 1259±1268.
Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V. 1998. Direct isolation,
phenotyping and cloning of low-frequency antigen-speci®c cytotoxic T lymphocytes from peri-
pheral blood. Curr Biol 8: 413±416.
Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon
DF, Sullivan JS. 1999. Strong human immunode®ciency virus (HIV)-speci®c cytotoxic T- lym-
